Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Immatics N.V. IMTX
$9.86
+$0.41 (4.12%)
На 18:02, 12 мая 2023
+183.98%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
759808579.00000000
-
week52high
13.60
-
week52low
5.75
-
Revenue
172831000
-
P/E TTM
47
-
Beta
0.47458100
-
EPS
0.81000000
-
Last Dividend
0.00000000
-
Next Earnings Date
22 мая 2023 г. в 10:59
Описание компании
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 17 мар 2021 г. |
| Goldman Sachs | Buy | 22 сент 2020 г. | |
| SVB Leerink | Outperform | Outperform | 27 июл 2020 г. |
| Jefferies | Buy | Buy | 24 июл 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Volume Breakout Report Update: Buy Eton Pharmaceuticals
Seeking Alpha
16 янв 2023 г. в 22:41
A number of VBR "green energy" picks have popped higher in January, pulling investment returns for the group of past picks strongly higher. A performance review of 46 previous selections since late June is discussed.
Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
17 ноя 2022 г. в 09:47
Immatics (IMTX) delivered earnings and revenue surprises of -3.23% and 13.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Immatics (IMTX) Moves 11.6% Higher: Will This Strength Last?
Zacks Investment Research
11 окт 2022 г. в 11:17
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Is Immatics (IMTX) Stock Up 7% Today?
InvestorPlace
10 окт 2022 г. в 10:24
Source: CI Photos / Shutterstock.com Immatics (NASDAQ: IMTX ) stock is climbing higher on Monday after the clinical-stage biopharmaceutical company revealed details of an underwritten public offering. Immatics has agreed to sell up to 10,905,000 shares of IMTX stock for a price of $10.09 each.
Strength Seen in Immatics (IMTX): Can Its 18% Jump Turn into More Strength?
Zacks Investment Research
20 июл 2022 г. в 10:08
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.